1. 1812 Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival. Retrospective analyses of the STO3 randomizedtrial. (September 2015) Authors: Lindström, L.S.; Yau, C.; Czene, K.; Thompson, C.K.; Van't Veer, L.J.; Nordenskjöld, B.; Stål, O.; Fornander, T.; Benz, C.C.; Borowsky, A.D.; Esserman, L.J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A novel biomarker to predict DNA-Repair-inhibitor response in stage I-III high risk breast cancer patients. (November 2022) Authors: Barcaru, A.; Kuilman, M.M.; Wolf, D.; Yau, C.; Choy, E.B.M.; Audeh, W.M.; Brown-Swigart, L.; Hirst, G.L.; Symmans, F.W.; Liu, M.C.; Nanda, R.; Esserman, L.J.; van 't Veer, L.J.; Glas, A.M.; Mittempergher, L. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Precision surgery and avoiding over-treatment. Issue 5 (May 2017) Authors: Hosseini, A.; Khoury, A.L.; Esserman, L.J. Journal: European journal of surgical oncology Issue: Volume 43:Issue 5(2017:May) Page Start: 938 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗